Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Synaptosomal-associated protein 29 (SNAP29) is a member of the SNARE family of proteins crucial for multiple cellular membrane trafficking pathways, including intracellular vesicle fusion, autophagy, and recycling processes[1][3][7]. Unlike the more plasma-membrane-localized SNAP25, SNAP29 binds tightly to multiple syntaxin proteins, is predominantly found on intracellular membrane structures, and also exists in the cytoplasm[1][3][5]. SNAP29 is directly involved in autophagosome-lysosome fusion, modulates synaptic transmission by regulating SNARE complex disassembly, mediates various trafficking steps (including endocytosis and recycling), and plays a role in cell division through kinetochore formation[3][5][7]. Loss-of-function mutations in SNAP29 cause CEDNIK syndrome (cerebral dysgenesis, neuropathy, ichthyosis, keratoderma), a rare neurocutaneous congenital disease characterized by severe neurological, skin, and developmental abnormalities[2][4][6][8]. Experimental evidence from both mouse and zebrafish models confirms SNAP29's requirement for proper neuromuscular and skin development, autophagy, and cell death regulation[4][6]. SNAP29 interacts with syntaxin family members, EHD1, and is associated with abnormal synaptic activity when its levels are altered, highlighting its role as a therapeutic target for diseases of membrane trafficking and neurodevelopment[5][6][7]. There are currently no drugs directly targeting SNAP29, and therapeutic interventions remain investigational[7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Synaptosomal-associated protein 29 (SNAP29).